GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
390
c/trialwatch·posted 11 months ago by u/pancreatitis_scare

why does nobody talk about SELECT

Trial Data Receipts ×5

Something I noticed reading old threads that I have not seen said out loud.

The advice on TRIUMPH in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.

I have listed what I think the current consensus is below. Correct me — that is the point of posting it.

403 up / 13 down97% upvoted17 commentsid 5stlh912 Aug 2025

17 comments

8 in this archive, depth 3

best — the order this archive was captured in

u/renal_outcomes_rnephro-curious57 points·11 months ago

SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/alcohol_aversion26 points·11 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/milos_trevino18 points·11 months ago·edited

This is correct. Discontinuation arms show the regain reality.

replysharereportpermalink
u/pancreatitis_scareOP23 points·11 months ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink
u/naomi_ekstrom9 points·11 months ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/nikhil_lindqvist34 points·11 months ago

Is that absolute or relative risk reduction?

replysharereportpermalink
u/piotr_bruun8 points·11 months ago·edited

the discontinuation arms are the interesting part, not the FLOW endpoints

replysharereportpermalink
u/sofia_ferreira12 points·11 months ago

off-label use data is different from approved-indication data

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →